ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients

Slideset

Download these slides for information on current treatment options for patients with ER+/HER2- MBC who experience disease progression after endocrine therapy, with a focus on novel therapies in the post-CDK4/6 inhibitor setting.

Released: November 19, 2024

Expiration: November 18, 2025

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.